Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 302
- Registration Number
- NCT03086330
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1609
- Registration Number
- NCT03078478
- Locations
- 🇷🇸
Novo Nordisk Investigational Site, Nis, Serbia
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT03075670
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT03075644
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama, Kanagawa, Japan
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT03070704
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 868
- Registration Number
- NCT03061214
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Lviv, Ukraine
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 731
- Registration Number
- NCT03021187
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 243
- Registration Number
- NCT03018028
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT03015220
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
Phase 1
Completed
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 56
- Registration Number
- NCT03015207
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath